Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Receivables (2017 - 2025)

Assembly Biosciences has reported Receivables over the past 9 years, most recently at $974000.0 for Q4 2025.

  • Quarterly results put Receivables at $974000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $974000.0 (changed N/A YoY), and the annual figure for FY2025 was $974000.0, changed.
  • Receivables for Q4 2025 was $974000.0 at Assembly Biosciences, up from $912000.0 in the prior quarter.
  • Over the last five years, Receivables for ASMB hit a ceiling of $1.2 million in Q3 2022 and a floor of $43000.0 in Q4 2023.
  • Median Receivables over the past 5 years was $523500.0 (2022), compared with a mean of $562357.1.
  • Biggest five-year swings in Receivables: soared 180.95% in 2022 and later tumbled 95.44% in 2023.
  • Assembly Biosciences' Receivables stood at $336000.0 in 2021, then skyrocketed by 180.95% to $944000.0 in 2022, then tumbled by 95.44% to $43000.0 in 2023, then changed by 0.0% to $43000.0 in 2024, then skyrocketed by 2165.12% to $974000.0 in 2025.
  • The last three reported values for Receivables were $974000.0 (Q4 2025), $912000.0 (Q3 2025), and $43000.0 (Q1 2024) per Business Quant data.